Market technician Jonathan Krinsky analyzes the shift in market leadership from technology to healthcare amid recent ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the ...

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the 12th Annual BTIG MedTech, Digital Health, ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the ...

BTIG research firm reiterated its Buy rating and $21.00 price target for INmune Bio Inc. (NASDAQ:INMB), currently trading at ...

In a report released today, Ryan Zimmerman from BTIG maintained a Hold rating on Solventum Corporation (SOLV – Research Report). The company’s ...

What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...

Papa Johns’ blueprint under CEO Todd Penegor has several targets, from a return to core strength focus to data leverage to ...

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

On Monday, Instacart (CART) stock saw a decline, ending the day at $45.65 which represents a decrease of $-0.34 or -0.74% from the prior close of $45.99. The stock opened at $45.17 and touched a low ...

BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...